Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant
- PMID: 10082212
- DOI: 10.1016/s0014-2999(98)00909-1
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant
Abstract
In the human alpha7 nicotinic receptor, valine-274 in the pore-lining transmembrane-2 region was mutated to threonine to produce the variant human alpha7V274T, which was evaluated electrophysiologically following expression in Xenopus laevis oocytes. Inward current rectification was strong in human alpha7V274T as in the human alpha7 wild type nicotinic receptor. However, human alpha7V274T was 100-fold more sensitive to the nicotinic receptor agonists acetylcholine, (-)-nicotine and 1,1-dimethyl-4-phenylpiperazinium. Choline also activated human alpha7V274T (EC50 = 12 microM) and was 82-fold more potent than at human alpha7 wild type nicotinic receptor. (-)-Cotinine, (2,4)-dimethoxybenzylidene anabaseine (GTS-21) and 2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine (ABT-089), weak partial agonists at human alpha7 wild type, were much stronger agonists at human alpha7V274T with EC50 values of 70 microM, 4 microM and 28 microM and fractional activation values of 93%, 96% and 40%, respectively. However, (-)-lobeline, a human alpha7 wild type nicotinic receptor antagonist, and dihydro-beta-erythroidine, which activates chick mutagenized alpha7 nicotinic receptors, had only weak agonist-like activity at human alpha7V274T (< or = 4% of the maximal acetylcholine response). Methyllycaconitine, mecamylamine, d-tubocurarine and dihydro-beta-erythroidine retained antagonist activity and, indeed, appeared to be at least as potent at human alpha7V274T as at human alpha7 wild type. These results support and extend the concept that human nicotinic receptor pharmacology can be profoundly altered by single amino acid changes in the pore-lining segment.
Similar articles
-
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.J Pharmacol Exp Ther. 2009 Feb;328(2):364-70. doi: 10.1124/jpet.108.145292. Epub 2008 Nov 20. J Pharmacol Exp Ther. 2009. PMID: 19023041 Free PMC article. Review.
-
Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists.Neuropharmacology. 1998 Sep;37(9):1095-102. doi: 10.1016/s0028-3908(98)00110-5. Neuropharmacology. 1998. PMID: 9833639
-
Rhesus monkey alpha7 nicotinic acetylcholine receptors: comparisons to human alpha7 receptors expressed in Xenopus oocytes.Eur J Pharmacol. 2005 Nov 7;524(1-3):11-8. doi: 10.1016/j.ejphar.2005.08.043. Epub 2005 Nov 2. Eur J Pharmacol. 2005. PMID: 16266703
-
Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands.Eur J Pharmacol. 1998 Apr 17;347(1):131-9. doi: 10.1016/s0014-2999(98)00084-3. Eur J Pharmacol. 1998. PMID: 9650859
-
The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).Behav Brain Res. 2000 Aug;113(1-2):169-81. doi: 10.1016/s0166-4328(00)00211-4. Behav Brain Res. 2000. PMID: 10942043 Review.
Cited by
-
Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.Br J Pharmacol. 2009 Nov;158(6):1486-94. doi: 10.1111/j.1476-5381.2009.00426.x. Epub 2009 Oct 20. Br J Pharmacol. 2009. PMID: 19845675 Free PMC article.
-
Cotinine: Pharmacologically Active Metabolite of Nicotine and Neural Mechanisms for Its Actions.Front Behav Neurosci. 2021 Oct 21;15:758252. doi: 10.3389/fnbeh.2021.758252. eCollection 2021. Front Behav Neurosci. 2021. PMID: 34744656 Free PMC article. Review.
-
Receptor pharmacogenetics: relevance to CNS syndromes.Br J Clin Pharmacol. 2002 Oct;54(4):344-8. doi: 10.1046/j.1365-2125.2002.01679.x. Br J Clin Pharmacol. 2002. PMID: 12392580 Free PMC article. Review.
-
High Throughput Random Mutagenesis and Single Molecule Real Time Sequencing of the Muscle Nicotinic Acetylcholine Receptor.PLoS One. 2016 Sep 20;11(9):e0163129. doi: 10.1371/journal.pone.0163129. eCollection 2016. PLoS One. 2016. PMID: 27649498 Free PMC article.
-
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.J Pharmacol Exp Ther. 2009 Feb;328(2):364-70. doi: 10.1124/jpet.108.145292. Epub 2008 Nov 20. J Pharmacol Exp Ther. 2009. PMID: 19023041 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources